以模型为指导的药理动力学/药理动力学截止值的开发和对抗目标病原体的西塔弗洛克萨剂量方案的评估
Hailan Wu1,2,3, Yi Li1,2,3, Xin Li1,2,3
1Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Frontiers in pharmacology
|March 3, 2025
概括
这项研究确定了西塔素的药理动力学/药理动力学 (PK/PD) 切断值,以指导抗菌药物敏感性测试. 西塔floxacin 显示对肺炎链球菌的有效性,但对于 Pseudomonas aeruginosa 感染需要进一步验证.
科学领域:
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
- 临床药房 临床药房
背景情况:
- 对抗微生物药物的临床断点对于有效治疗至关重要.
- 西塔弗洛克萨是一种具有广谱活性的诺基诺抗生素.
- 建立药理动力学/药理动力学 (PK/PD) 切线线支持临床断点的发展.
研究的目的:
- 确定针对关键病原体的西塔弗洛克萨的PK/PD切断点.
- 支持建立抗微生物药物敏感性测试的临床断点.
- 为了评估不同西塔弗洛克萨剂量方案的疗效.
主要方法:
- 使用342名受试者的数据开发了一个人群药理动力学 (PopPK) 模型.
- 进行蒙特卡洛模拟,以计算实现目标的概率 (PTA) 和累积反应分数 (CFR).
- 应用了PK/PD目标 (fAUC24h/MIC) 来评估西塔弗洛克萨辛对*肺炎杆菌*,金色杆菌杆菌*,大肠杆菌*,肺炎杆菌*和肺炎假菌*的疗效.
主要成果:
- PopPK建模表明,肌素清除率,体重,年龄和食物摄入量会影响西塔弗洛克萨的药理学参数.
- 根据动物感染模型的目标 (fAUC24h/MIC = 11.56),西塔弗洛克萨在MIC ≤ 0.125 mg/L.的情况下,针对*S. pneumoniae*实现了>95%的PTA.
- 在临床标 (fAUC24h/MIC ≥30) 中,西塔弗洛克萨辛在MIC ≤0.06 mg/L的情况下,针对*S. pneumoniae*实现了>95%的PTA,MIC ≤0.06 mg/L. 对于其他病原体,PK/PD截止值在0.06至0.125 mg/L之间.
结论:
- 对于所研究的病原体,西塔弗洛克萨PK/PD的建议切断值为S ≤0.06 mg/L和R >0.125 mg/L.
- 预计西塔弗洛克萨辛 (50毫克每12小时,100毫克每24小时,100毫克每12小时) 的剂量方案对*S. pneumoniae*感染有效.
- 需要进行临床验证,以确认西塔弗洛克萨对P. aeruginosa感染的疗效.
相关概念视频
01:26Pharmacokinetic Models: Comparison and Selection Criterion
36
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
36
01:25Clearance Models: Compartment Models
45
Clearance measures drug elimination from the central compartment, including plasma and highly perfused organs like kidneys and liver. Its calculation varies depending on pharmacokinetic models and administration routes. The one-compartment model, for instance, portrays the pharmacokinetics of polar drugs such as aminoglycoside antibiotics administered intravenously and readily excreted in urine. In this case, clearance is influenced by the terminal rate constant (λz) and the total volume...
45
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
38
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
38
01:11Renal Failure: Dose Adjustments
54
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
54
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
24
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
24
01:24One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
327
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
On...
327